Jefferies reiterates Buy rating for Kenvue stock despite share decline

Investing.com

Published Jun 04, 2025 06:46AM ET

Jefferies reiterates Buy rating for Kenvue stock despite share decline

On Wednesday, Jefferies analysts reiterated their Buy rating for Kenvue Inc (NYSE: KVUE), maintaining a price target of $27.00. According to InvestingPro data, analyst targets range from $22 to $29, with the company maintaining impressive gross profit margins of 58.2%. The decision follows recent management commentary regarding April's destocking, a cautious consumer environment, and early seasonal trends, which were perceived as negative factors.

Despite these concerns, Jefferies noted that some of these issues were already anticipated and did not prompt a change in guidance. The analysts highlighted that the business is showing signs of recovery, with investments expected to support a full turnaround. The company generated $15.3 billion in revenue over the last twelve months, and InvestingPro analysis indicates net income growth is expected this year.

Shares of Kenvue fell by 6% on Tuesday, which Jefferies analysts view as an opportunity for the company to pursue a self-help transformation. The analysts believe that the market's reaction to the recent commentary may have been overstated.

Kenvue, a company listed on the New York Stock Exchange, continues to navigate a challenging consumer landscape, yet remains focused on its recovery strategy.

In other recent news, Kenvue Inc. (NYSE:KVUE) reported $15.5 billion in sales for the fiscal year 2024, marking its debut on the Fortune 500 list at number 281. The company also announced the issuance of $750 million in Senior Notes, with plans to use the proceeds for general corporate purposes. During its 2025 Annual Meeting of Shareholders, Kenvue's shareholders approved the election of all 13 director nominees and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025. In analyst updates, Canaccord Genuity maintained a Buy rating on Kenvue, setting a price target of $29.00, and noted a potential 33% upside if the company can enhance its operations, particularly within its Skin Health & Beauty segment. CEO Thibaut Mongon recently addressed seasonal demand challenges at a conference, citing a longer winter as a factor impacting allergy and sun care product sales. The company is also experiencing shipment delays due to US retailers' de-stocking in response to the current tariff environment. These developments reflect ongoing challenges and strategic decisions facing Kenvue as it navigates its position in the consumer health sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes